Shutting Down Multiple sclerosis (MS) : New Insights on Induction, Escalation, Oral Agents, and Monitoring is organized by Vindico Medical Education.
Release Date: 3/28/2018
The intended audience for this activity is neurologists and other health care professionals involved in the treatment of patients with relapsing-remitting MS (RRMS).
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disorder of the central nervous system, with a variable disease course. Approximately 85% of patients are diagnosed with relapsing–remitting MS (RRMS); of these, 50% to 60% progress after 10 to 20 years to secondary progressive MS, which is characterized by continuously worsening disability, without periods of remission. Treatment decisions for patients with RRMS are increasingly challenging as new agents rapidly emerge in the therapeutic landscape. Two different strategies for treatment have emerged—an “escalation” paradigm in which therapies with the least potential for toxicities are first utilized and an alternative “induction” approach in which more powerful treatments are initiated. In this CME activity, experts will evaluate these 2 management strategies, including the efficacy and safety data for oral agents used in the treatment of patients with RRMS. Monitoring patients for response, safety, tolerability, and adherence to prescribed RRMS therapies will also be reviewed.
Upon successful completion of this educational activity, participants should be better able to:
• Apply relapse and disability outcomes for induction therapy vs. escalation therapy in the treatment of patients with RRMS.
• Evaluate efficacy and safety data for oral agents used in the treatment of patients with RRMS.
• Incorporate strategies for monitoring patients for response, safety, tolerability, and adherence to prescribed RRMS therapies.
Additional details will be posted as soon as they are available.